Microsoft Strikes $2.8B Cloud-Computing Deal With London Stock Exchange Group – $MSFT $AMZN $GOOG $INVO

By John F. Heerdink, Jr.

As per reports, Microsoft (MSFT) has agreed to buy a 4% stake in London Stock Exchange Group Plc in a $2.8B cloud-computing deal pushing the tech giant further into financial market data world. As part of the agreement, London Stock Exchange Group Plc is to spend at least that amount on cloud services with Microsoft over the next 10 years. The initiative will speed up the migration of its markets to the cloud and allow it to develop new products and services.

The partnership adds to a recent trend of exchanges and tech firms like partnerships between Nasdaq Inc. and Amazon.com Inc. (AMZN), as well as Alphabet Inc.’s Google (GOOG) and CME Group, pointing towards increased demand from investors giving them an edge in increasingly fast electronic markets.

“We will be generating meaningful revenue growth in the coming years by accessing new products and enhancing our existing product capabilities,” stated LSEG Chief Executive Officer David Schwimmer said in a phone interview.

Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses supports, and sells computer software, consumer electronics, personal computers, and related services. To learn more about Microsoft (MSFT) and to track their progress please visit the Vista Partners Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

DID YOU KNOW?

The current birth rate for U.K. in 2022 is 11.322 births per 1000 people which equates to a .48% decline from 2021.

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.